• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

    1/25/24 5:27:04 PM ET
    $SILO
    Apparel
    Consumer Discretionary
    Get the next $SILO alert in real time by email
    SC 13G/A 1 ea192209-13ga2reda_silo.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2(b)

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (AMENDMENT NO. 2)

     

    Silo Pharma, Inc.

     

    (Name of Issuer)

     

    Common Shares, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    (CUSIP Number)

     82711P201

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the Rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d – 1(b)
      ☒ Rule 13d – 1(c)
      ☐ Rule 13d – 1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 82711P201

     

    1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Joseph Reda

    2.

    Check The Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    U.S.

    Number of
    Shares
    Beneficially
    Owned By
    Each
    Reporting
    Person With
    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    0

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person
    0

    10. 

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐

    11. 

    Percent of Class Represented By Amount in Row (9)
    0%(1)

    12. 

    Type of Reporting Person (See Instructions)
    IN

     

    (1)

    Based on 3,108,797 shares of Common Stock outstanding as of November 13, 2023.

     

    -1-

     

     

    CUSIP No. 82711P201

     

    1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Joseph Reda C/F Dustin Russell Reda UTMA/NY

    2.

    Check The Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    U.S.

    Number of
    Shares
    Beneficially
    Owned By
    Each
    Reporting
    Person With
    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    0

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person
    0

    10. 

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ☐

    11. 

    Percent of Class Represented By Amount in Row (9)
    0%(1)

    12. 

    Type of Reporting Person (See Instructions)
    OO

     

    (1)

    Based on 3,108,797 shares of Common Stock outstanding as of November 13, 2023.

     

    -2-

     

     

    CUSIP No. 82711P201

     

    1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Joseph Reda C/F Joseph William Reda UTMA/NY

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3. SEC Use Only
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    0

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0

    10. 

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐

    11. 

    Percent of Class Represented By Amount in Row (9)
    0%(1)

    12. 

    Type of Reporting Person (See Instructions)
    OO

     

    (1)

    Based on 3,108,797 shares of Common Stock outstanding as of November 13, 2023.

     

    -3-

     

     

    CUSIP No. 82711P201

     

    1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Joseph Reda C/F Angus Patrick Deeney UTMA/NY

    2.

    Check The Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    U.S.

    Number of
    Shares
    Beneficially
    Owned By
    Each
    Reporting
    Person With
    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    0

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person
    0

    10. 

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐

    11. 

    Percent of Class Represented By Amount in Row (9)
    0%(1)

    12. 

    Type of Reporting Person (See Instructions)
    OO

     

    (1)

    Based on 3,108,797 shares of Common Stock outstanding as of November 13, 2023.

     

    -4-

     

     

    CUSIP No. 82711P201

     

    1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Joseph Reda C/F Claire Estie Deeney UTMA/NY

    2.

    Check The Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    U.S.

    Number of
    Shares
    Beneficially
    Owned By
    Each
    Reporting
    Person With
    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    0

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person
    0

    10. 

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐

    11. 

    Percent of Class Represented By Amount in Row (9)
    0%(1)

    12. 

    Type of Reporting Person (See Instructions)
    OO

     

    (1)

    Based on 3,108,797 shares of Common Stock outstanding as of November 13, 2023.

     

    -5-

     

     

    Item 1(a). Name of Issuer:
       
      Silo Pharma, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ 07632
       
    Item 2(a). Name of Person Filing.
       
     

    The statement is filed on behalf of Joseph Reda, Joseph Reda C/F Dustin Russell Reda UTMA/NY (“DRR UTMA”), Joseph Reda C/F Joseph William Reda UTMA/NY (“JWR UTMA”), Joseph Reda C/F Angus Patrick Deeney UTMA/NY (“APD UTMA”), and Joseph Reda C/F Claire Estie Deeney UTMA/NY (“CED UTMA”)(collectively, the “Reporting Persons”).

     

    Mr. Reda is also the custodian of each of DRR UTMA, JWR UTMA, APD UTMA, and CED UTMA and in such capacity each has voting and dispositive power over the securities held by each such entity.

       
    Item 2(b). Address of Principal Business Office or, if None, Residence.
       
     

    The address for Reporting Persons is:

    1324 Manor Circle Pelham, NY 10803

       
    Item 2(c). Citizenship.
     

    U.S.

     

    UTMA, JWR UTMA, APD UTMA, and CED UTMA are each organized under the laws of the State of New York.

       
    Item 2(d). Title of Class of Securities.
       
      Common Shares
       
    Item 2(e). CUSIP Number.
      82711P201
       
    Item 3. Type of Person.
       
      Not applicable.
       
    Item 4. Ownership.
       
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each of the Reporting Persons hereto, including footnotes, and is incorporated herein by reference for the Reporting Persons. The percentage set forth in Row (11) of the cover page for each of the Reporting Persons are calculated based on 3,108,797 shares of Common Stock outstanding as of November 13, 2023, as disclosed on the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2023.

     

    -6-

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company.
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not applicable.
       
    Item 10. Certifications.
       
      Not applicable

     

    -7-

     

     

    SIGNATURE PAGE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  January 25, 2024   By: /s/ Joseph Reda
        Name: Joseph Reda
         
    Dated:  January 25, 2024   Joseph Reda C/F Dustin Russell Reda UTMA/NY
         
        By: /s/ Joseph Reda
        Name:  Joseph Reda
        Title: Custodian
         
    Dated: January 25, 2024   Joseph Reda C/F Joseph William Reda UTMA/NY
         
        By: /s/ Joseph Reda
        Name: Joseph Reda
        Title: Custodian
         
    Dated: January 25, 2024   Joseph Reda C/F Angus Patrick Deeney UTMA/NY
         
        By: /s/ Joseph Reda
        Name: Joseph Reda
        Title: Custodian
         
    Dated: January 25, 2024   Joseph Reda C/F Claire Estie Deeney UTMA/NY
         
        By: /s/ Joseph Reda
        Name: Joseph Reda
        Title: Custodian

     

    -8-

    Get the next $SILO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SILO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SILO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Silo Pharma Announces Closing of $2 Million Public Offering

      SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants ("Series A-1 Warrants") to purchase up to 3,333,338 shares of common stock and series A-2 warrants ("Series A-2 Warrants") to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warran

      5/16/25 4:15:00 PM ET
      $SILO
      Apparel
      Consumer Discretionary
    • Silo Pharma Announces Pricing of $2 Million Public Offering

      SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants ("Series A-1 Warrants") to purchase up to 3,333,338 shares of common stock and series A-2 warrants ("Series A-2 Warrants") to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant.

      5/15/25 9:15:00 AM ET
      $SILO
      Apparel
      Consumer Discretionary
    • Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

      SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). "We look forward to working with Veloxity Labs for GLP sample analysis in our current safety study of SPC-15," said Eric Weisblum, CEO of Silo. "We expect Veloxity to p

      5/14/25 4:07:00 PM ET
      $SILO
      Apparel
      Consumer Discretionary

    $SILO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

      4 - Silo Pharma, Inc. (0001514183) (Issuer)

      12/16/24 5:00:06 PM ET
      $SILO
      Apparel
      Consumer Discretionary
    • CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

      4 - Silo Pharma, Inc. (0001514183) (Issuer)

      11/22/24 4:16:10 PM ET
      $SILO
      Apparel
      Consumer Discretionary
    • CEO and President Weisblum Eric bought $5,533 worth of shares (5,000 units at $1.11), increasing direct ownership by 3% to 180,432 units (SEC Form 4)

      4 - Silo Pharma, Inc. (0001514183) (Issuer)

      6/13/24 1:19:05 PM ET
      $SILO
      Apparel
      Consumer Discretionary

    $SILO
    SEC Filings

    See more
    • Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Silo Pharma, Inc. (0001514183) (Filer)

      5/16/25 4:30:32 PM ET
      $SILO
      Apparel
      Consumer Discretionary
    • SEC Form 424B4 filed by Silo Pharma Inc.

      424B4 - Silo Pharma, Inc. (0001514183) (Filer)

      5/16/25 9:08:42 AM ET
      $SILO
      Apparel
      Consumer Discretionary
    • SEC Form EFFECT filed by Silo Pharma Inc.

      EFFECT - Silo Pharma, Inc. (0001514183) (Filer)

      5/16/25 12:15:16 AM ET
      $SILO
      Apparel
      Consumer Discretionary

    $SILO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

      4 - Silo Pharma, Inc. (0001514183) (Issuer)

      12/16/24 5:00:06 PM ET
      $SILO
      Apparel
      Consumer Discretionary
    • CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

      4 - Silo Pharma, Inc. (0001514183) (Issuer)

      11/22/24 4:16:10 PM ET
      $SILO
      Apparel
      Consumer Discretionary
    • CEO and President Weisblum Eric bought $5,533 worth of shares (5,000 units at $1.11), increasing direct ownership by 3% to 180,432 units (SEC Form 4)

      4 - Silo Pharma, Inc. (0001514183) (Issuer)

      6/13/24 1:19:05 PM ET
      $SILO
      Apparel
      Consumer Discretionary

    $SILO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Silo Pharma Inc.

      SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

      7/26/24 4:17:36 PM ET
      $SILO
      Apparel
      Consumer Discretionary
    • SEC Form SC 13G filed by Silo Pharma Inc.

      SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

      6/13/24 5:08:53 PM ET
      $SILO
      Apparel
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

      SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)

      1/25/24 5:27:04 PM ET
      $SILO
      Apparel
      Consumer Discretionary